Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

• Published in: EuroIntervention Vol. 18; no. 9; pp. 709 - 718
• Main Authors: Emilsson, Oskar Love, Bergman, Sofia, Mohammad, Moman A, Olivecrona, Göran K, Götberg, Matthias, Erlinge, David, Koul, Sasha
• Format: Journal Article
• Language: English
• Published: France Europa Edition 21.10.2022
• Subjects: Angioplasty, Balloon, Coronary; Bleeding; Cardiac and Cardiovascular Systems; Clinical Medicine; Clinical Research; Coronary Angiography; Coronary Occlusion; Coronary Occlusion - etiology; Hemorrhage - chemically induced; Heparin; Heparin - therapeutic use; Humans; Kardiologi; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Mortality; Percutaneous Coronary Intervention - adverse effects; Pretreatment; Registries; ST Elevation Myocardial Infarction - diagnostic imaging; ST Elevation Myocardial Infarction - etiology; ST Elevation Myocardial Infarction - therapy; STEMI; Sweden; Treatment Outcome; Sweden
• ISSN: 1774-024X; 1969-6213
• DOI: 10.4244/EIJ-D-22-00432

Unfractionated heparin (UFH) is frequently administered before percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). The aim of the study was to investigate if pretreatment with UFH prior to arrival at the catheterisation laboratory affects coronary artery occlusion, mortality, and in-hospital major bleeding in patients with STEMI undergoing PCI. Patients with a first STEMI event undergoing PCI between 2008 and 2016 were extracted from the Swedish Coronary Angiography and Angioplasty Registry. Risk ratios for UFH pretreatment versus no pretreatment regarding coronary artery occlusion at presentation in the catheterisation laboratory, 30-day mortality, and bleeding were obtained using adjusted Poisson regression models with robust standard errors. Analyses of propensity score (PS)-matched groups were performed to obtain absolute risk differences. In all, 41,631 patients were included, 16,026 (38%) with and 25,605 (62%) without UFH pretreatment. Adjusted risk ratios were 0.89 (95% confidence interval [CI]: 0.87 to 0.90) for coronary artery occlusion, 0.87 (0.77 to 0.99) for mortality, and 1.01 (0.86 to 1.18) for bleeding. In the PS-matched analyses, the absolute risk differences were -0.087 (-0.074 to -0.099) for coronary artery occlusion, -0.011 (-0.017 to -0.0041) for mortality, and 0 (-0.0052 to 0.0052) for bleeding. Pretreatment with UFH was associated with a reduction in coronary artery occlusion among patients with STEMI, with a number needed to treat (NNT) of 12, without increasing the risk of major in-hospital bleeding. Regarding mortality, a reduction was found with UFH pretreatment, with an NNT of 94, but this effect was not robust over all sensitivity analyses and residual confounding cannot be excluded.